The modified Baveno classification for obstructive sleep apnoea management

<bold>Aim:</bold> The Baveno classification for obstructive sleep apnoea (OSA) (2021) incorporates symptoms and comorbidities. We analysed how including cardiovascular disease (CVD) risk and a high apnoea-hypopnoea index (AHI) of ≥30/h affects treatment recommendation. <bold>Method:</bold> 8,548 OSA patients from the European Sleep Apnoea Data Base (ESADA) were retrospectively allocated into both the original Baveno classification and to the modified Baveno classification. In the modified Baveno, AHI ≥30/h equalled high treatment indication. For remaining patients symptoms and CVD risk assessment (using SCORE2 and European Society of Cardiology 2021 guidelines) enabled classification into low, intermediate or high treatment indication group. The differences in resulting treatment indication were compared. <bold>Results:</bold> Figure 1 shows the changes in risk stratification and OSA treatment indication. The modified Baveno puts a further 47.0% of patients into the high treatment indication group compared to the original Baveno, whereas 39.8% of cases did not change. AHI ≥30/h was the main factor driving 36.7% of patients from low or intermediate into the high treatment recommendation group. CVD risk assessment put a further 16.7% of patients into a higher treatment recommendation group. <fig><object-id>erj;64/suppl_68/PA861/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig> <bold>Discussion:</bold> The modified Baveno identifies different and more high treatment indication cases compared to the original Baveno. A prospective study is needed to assess for clinical relevance.

Authors

Institutions

Publication Details

Published
2024-09-14
DOI
https://doi.org/10.1183/13993003.congress-2024.pa861
Primary Topic
Obstructive Sleep Apnea Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The modified Baveno classification for obstructive sleep apnoea management

Sébastien Bailly, Gianfranco Parati, Sophia E. Schiza, Özen K. Başoğlu et al.
Obstructive Sleep Apnea Research
article

The modified Baveno classification for obstructive sleep apnoea management

Sébastien Bailly, Gianfranco Parati, Sophia E. Schiza, Özen K. Başoğlu, Sandhya Matthes, Winfried Johannes Randerath, Marcel Treml, Ludger Grote, Walter Mcnicholas, Johan A. Verbraecken, Jean‐Louis Pépin, Athanasia Pataka, Maria Rosaria Bonsignore, Ding Zou, Carolina Lombardi, Paweł Śliwiński, Renaud Tamisier, Stephen J. Ryan, Jan Hedner
article en

Abstract

<bold>Aim:</bold> The Baveno classification for obstructive sleep apnoea (OSA) (2021) incorporates symptoms and comorbidities. We analysed how including cardiovascular disease (CVD) risk and a high apnoea-hypopnoea index (AHI) of ≥30/h affects treatment recommendation. <bold>Method:</bold> 8,548 OSA patients from the European Sleep Apnoea Data Base (ESADA) were retrospectively allocated into both the original Baveno classification and to the modified Baveno classification. In the modified Baveno, AHI ≥30/h equalled high treatment indication. For remaining patients symptoms and CVD risk assessment (using SCORE2 and European Society of Cardiology 2021 guidelines) enabled classification into low, intermediate or high treatment indication group. The differences in resulting treatment indication were compared. <bold>Results:</bold> Figure 1 shows the changes in risk stratification and OSA treatment indication. The modified Baveno puts a further 47.0% of patients into the high treatment indication group compared to the original Baveno, whereas 39.8% of cases did not change. AHI ≥30/h was the main factor driving 36.7% of patients from low or intermediate into the high treatment recommendation group. CVD risk assessment put a further 16.7% of patients into a higher treatment recommendation group. <fig><object-id>erj;64/suppl_68/PA861/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig> <bold>Discussion:</bold> The modified Baveno identifies different and more high treatment indication cases compared to the original Baveno. A prospective study is needed to assess for clinical relevance.

University of Crete (GR), Inserm (FR), Centre Hospitalier Universitaire de Grenoble (FR), Sahlgrenska University Hospital (SE), Ege University (TR), Antwerp University Hospital (BE), St. Vincent's University Hospital (IE), National Center for Tuberculosis and Lung Disease (GE), Krankenhaus Bethanien (DE), Institute for Biomedical Research and Innovation (IT), IRCCS Istituto Auxologico Italiano (IT), Grenoble Institute of Neurosciences (FR), G. Papanikolaou General Hospital (GR), Université Grenoble Alpes (FR)
Good health and well-being
Openalex Percentile: Top 72%
Obstructive Sleep Apnea Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.